RevBio, Inc.

The RevBio team had a fantastic time at the 2026 Annual Meeting in San Antonio last week. Thank you to the many attendees who came by our booth to learn about TETRANITE®, our regenerative bone adhesive technology. It was a pleasure to share how our innovative biomaterial will reduce the duration and complexity of neurosurgical procedures, allow for more minimally invasive surgeries, lessen patient pain and recovery time, and reduce the overall cost of care with clinicians and leaders in the neuro community.
 
Key conversations with new connections from AANS were focused on RevBio’s exciting clinical progress updates. Our upcoming multi-center randomized controlled pivotal clinical trial will determine the safety and efficacy of TETRANITE® to reintegrate cranial bone flaps. Read more about this upcoming trial, here: https://www.businesswire.com/news/home/20260127271652/en/FDA-Greenlights-RevBios-Pivotal-Clinical-Trial-for-its-Cranial-Flap-Bone-Glue
 

RevBio is at the 2026 Annual Meeting this weekend in San Antonio, TX! Our team will share how ® regenerative bone adhesive is transforming the future of skull-based procedures at booth 1113 in the exhibit hall. Attendees will get a chance to experience the unique properties of the biomaterial; especially how easy it is to apply and how strong the glue is in fixating cranial flaps compared to plates and screws.

AANS featured speaker and RevBio’s CMO Dr. Kevin Foley, will be presenting throughout the weekend. See the full program schedule, here: https://aans2026.eventscribe.net/

Happy to be here in Texas!

ClinicalTrials MedicalDevice CranialFlapFixation BoneAdhesive RegenerativeMedicine FDA

Happy New Year from RevBio! Take a look at our monthly highlights from 2025. 🎉

We are excited to carry the momentum from this past year right into 2026! 

Our team is laser-focused on continuing the clinical evaluation on our leading indications consisting of cranial flap fixation, dental implant stabilization, extremity fracture fixation, and dental bone grafting. The regulatory process continues to validate TETRANITE®’s safety and efficacy as the only regenerative bone glue. 

2026 promises to be a watershed year for raising capital to scale patient enrollment and complete our ongoing FDA approved pivotal trials. 

We would like to thank our employees, investors, and collaborators for another successful year of working towards commercialization of the revolutionary TETRANITE® product platform.